Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for ABT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1993. Start Trial.
Date Value
June 30, 2026 -3.518B
March 31, 2026 17.31B
December 31, 2025 -1.397B
September 30, 2025 -1.76B
June 30, 2025 -1.097B
March 31, 2025 -2.055B
December 31, 2024 -1.861B
September 30, 2024 -1.576B
June 30, 2024 -791.00M
March 31, 2024 -1.176B
December 31, 2023 -2.052B
September 30, 2023 -2.34B
June 30, 2023 -1.289B
March 31, 2023 -1.41B
December 31, 2022 -1.457B
September 30, 2022 -1.543B
June 30, 2022 -813.00M
March 31, 2022 -3.823B
December 31, 2021 -1.886B
September 30, 2021 -1.377B
June 30, 2021 -1.264B
March 31, 2021 -967.00M
December 31, 2020 -787.00M
September 30, 2020 -1.915B
June 30, 2020 658.00M
Date Value
March 31, 2020 -735.00M
December 31, 2019 -2.185B
September 30, 2019 -513.00M
June 30, 2019 -449.00M
March 31, 2019 -1.142B
December 31, 2018 -4.776B
September 30, 2018 2.471B
June 30, 2018 -1.631B
March 31, 2018 -6.455B
December 31, 2017 -112.00M
September 30, 2017 -386.00M
June 30, 2017 -384.00M
March 31, 2017 -4.399B
December 31, 2016 13.50B
September 30, 2016 -746.00M
June 30, 2016 -179.00M
March 31, 2016 -1.432B
December 31, 2015 -497.00M
September 30, 2015 -815.00M
June 30, 2015 -374.00M
March 31, 2015 -550.00M
December 31, 2014 -700.00M
September 30, 2014 -271.00M
June 30, 2014 -619.00M
March 31, 2014 -1.152B

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Becton, Dickinson & Co. -651.00M
Boston Scientific Corp. -410.00M
DexCom, Inc. -607.30M
Insulet Corp. 4.00M
Intuitive Surgical, Inc. -287.90M